CoChat

The interactions of p53 with tau and Aß as potential therapeutic targets for Alzheimer’s disease

Open access
Jazvinšćak Jembrek, Maja, Slade, Neda, Hof, Patrick R., Šimić, Goran · 2018 · Progress in Neurobiology
Cited by 100

The DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.

Abstract

&NA; Alzheimer's disease (AD), the most common progressive neurodegenerative disorder, is characterized by severe cognitive decline and personality changes as a result of synaptic and neuronal loss. The defining clinicopathological hallmarks of the disease are deposits of amyloid precursor protein (APP)‐derived amyloid‐&bgr; peptides (A&bgr;) in the brain parenchyma, and intracellular aggregates of truncated and hyperphosphorylated tau protein in neurofibrillary tangles (NFT). At the cellular and molecular levels, many intertwined pathological mechanisms that relate A&bgr; and tau pathology with a transcription factor p53 have been revealed. p53 is activated in response to various stressors that threaten genomic stability. Depending on damage severity, it promotes neuronal death or survival, predominantly via transcription‐dependent mechanisms that affect expression of apoptosis‐related target genes. Levels of p53 are enhanced in the AD brain and maintain sustained tau hyperphosphorylation, whereas intracellular A&bgr; directly contributes to p53 pool and promotes downstream p53 effects. The review summarizes the role of p53 in neuronal function, discusses the interactions of p53, tau, and A&bgr; in the normal brain and during the progression of AD pathology, and considers the impact of the most prominent hereditary risk factors of AD on p53/tau/A&bgr; interactions. A better understanding of this intricate interplay would provide deeper insight into AD pathology and might offer some novel therapeutic targets for the improvement of treatment options. In this regard, drugs and natural compounds targeting the p53 pathway are of growing interest in neuroprotection as they may represent promising therapeutic approaches in the prevention of oxidative stress‐dependent pathological processes underlying AD. HighlightsAccumulation of A&bgr; peptides and hyperphosphorylated tau proteins are defining hallmarks of AD.Transcription factor p53 promotes neuronal death or survival via transcription‐dependent mechanisms.Levels of p53 are enhanced in the AD brain maintaining tau hyperphosphorylation.Soluble A&bgr; oligomers increase p53 amount and activity promoting downstream p53 effects.The interactions of p53 with tau and A&bgr; represent potential p53‐based therapeutics for AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.pneurobio.2018.05.001

Cites

102 of 102 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 102 references

Cited by

See all 100

Metadata

Authors
Jazvinšćak Jembrek, M., Slade, N., Hof, P. R., & Šimić, G.
Venue
Progress in Neurobiology
Publisher
Elsevier BV
Published
2018-09
Volume
168
Pages
104-127
ISSN
0301-0082 (ISSN-L)
OpenAlex
W2802814977
Cited by
100
References
102
FWCI
7.57
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The interactions of p53 with tau and Aß as potential therapeutic targets for Alzheimer’s disease. https://app.cochat.ai/papers/10.1016/j.pneurobio.2018.05.001
The paper
Jazvinšćak Jembrek, M., Slade, N., Hof, P. R., & Šimić, G. (2018). The interactions of p53 with tau and Aß as potential therapeutic targets for Alzheimer’s disease. Progress in Neurobiology. https://doi.org/10.1016/j.pneurobio.2018.05.001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.